Relationship between osteopontin blood marker and relapse, remission of multiple sclerosis in Saudi Arabia 2024

Article Sidebar

PDF
Published: Nov 12, 2024
Keywords:
biomarker, multiple sclerosis, osteopontin

Main Article Content

Hakami Badriah Hafiz M
Specialist-Laboratory, Prince Muhammad bin Nasser Hospital in Jazan, Saudi Arabia.
Alqassemi Halima Omar Q
Specialist-Laboratory, Jazan Specialist Hospital, Saudi Arabia.
Alhazmy Ali Yahya M
Technician-Laboratory, Prince Mohammed bin Nasser Hospital, Saudi Arabia.
Mabar Ahmed Mohammed A
Technician-Laboratory, Prince Mohammed bin Nasser Hospital, Saudi Arabia.
Ibrahim Hassan J Dawmari
Technician-Laboratory, Prince Mohammed bin Nasser Hospital, Saudi Arabia.
Mashlawi Waleed Qasem H
Technician-Laboratory, Prince Mohammed bin Nasser Hospital, Saudi Arabia.
Alqasimi Ali Omar Q
Technician-Laboratory, Prince Mohammed bin Nasser Hospital, Saudi Arabia.
Tami Abdulrahman Ibrahim A
Technician-Laboratory, Prince Mohammed bin Nasser Hospital, Saudi Arabia.
Malhan Ali Hamad A
Technician-Laboratory, King Fahd Central Hospital, Saudi Arabia.
Eman Ayed Al anazi
Laboratory specialist, Prince Mohammed bin abdulaziz (Riyadh), Saudi Arabia.
Arwa Hasan Alahmadi
Laboratory Specialist, Regional Laboratory in Makkah, Saudi Arabia.

Abstract

Background: Osteopontin (OPN) is a widely expressed acidic glycoprotein, and is considered as an interesting biomarker because of its role in the pathophysiology of several inflammatory, degenerative, autoimmune, and oncologic diseases. This study aimed to evaluate Relationship between osteopontin blood marker and relapse, remission of multiple sclerosis in Saudi Arabia patients in 2024 and correlate it with disease activity.

Article Details

Issue
Vol. 27 No. 2S (2024): Sustainable Engineering Practices in Medical Laboratories
Section
Articles
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.